The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
about
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The addition of idarucizumab t ...... nosis of hemostasis disorders.
@en
The addition of idarucizumab t ...... nosis of hemostasis disorders.
@nl
type
label
The addition of idarucizumab t ...... nosis of hemostasis disorders.
@en
The addition of idarucizumab t ...... nosis of hemostasis disorders.
@nl
prefLabel
The addition of idarucizumab t ...... nosis of hemostasis disorders.
@en
The addition of idarucizumab t ...... nosis of hemostasis disorders.
@nl
P2093
P2860
P356
P1476
The addition of idarucizumab t ...... nosis of hemostasis disorders.
@en
P2093
I Vanlinthout
I van Horenbeeck
J Schoeters
K Peerlinck
M Jacquemin
M Peetermans
P Verhamme
P2860
P304
P356
10.1111/JTH.13138
P577
2015-09-08T00:00:00Z